Premium
Tetraspan myelin protein PMP22 and demyelinating peripheral neuropathies: New facts and hypotheses
Author(s) -
Müller Hans W.
Publication year - 2000
Publication title -
glia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.954
H-Index - 164
eISSN - 1098-1136
pISSN - 0894-1491
DOI - 10.1002/(sici)1098-1136(20000115)29:2<182::aid-glia12>3.0.co;2-k
Subject(s) - biology , myelin , endoplasmic reticulum , golgi apparatus , peripheral myelin protein 22 , microbiology and biotechnology , phenotype , mutant , transmembrane protein , neuroscience , genetics , gene , central nervous system , receptor
It has been demonstrated that abnormal levels of PMP22 expression due to altered gene dosage in CMT1A neuropathy alters Schwann cell growth and differentiation. On the other hand, disease‐related missense mutations within transmembrane domains of PMP22 disturb intracellular protein trafficking leading to accumulation of the mutant protein in the endoplasmic reticulum/Golgi compartment. Further, the recently reported association of PMP22 and P0 in peripheral myelin sheds new light on the almost identical phenotypes of CMT1A and CMT1B giving rise to a unifying hypothesis on disease mechanism. GLIA 29:182–185, 2000. © 2000 Wiley‐Liss, Inc.